Therapies database

Find a therapy. Follow the evidence.

See what is being studies, who is developing it, and how far it has progressed.

Search therapy records

Search a therapy, company, target, indication, or trial ID. Narrow by approach, stage, or status, then open a record to check its sources.

More filters and sort (1 active)

Company-led only

7 results

Therapy	Approach	Progress	Population	Additional Info
AC102 by AudioCure PharmaAudioCure Pharma Compare	Small Molecule	Stage: Phase 2Status: Active	Adults · 18–85 yearsRecent severe unilateral ISSNHL
SPI-1005 by Sound PharmaceuticalsSound Pharmaceuticals Compare	Small Molecule	Stage: Phase 3Status: Active	Adults · 18–75 yearsActive Ménière’s disease
OTO-313 by OtonomyOtonomy Compare	Small Molecule	Stage: Phase 2Status: Discontinued	Adults · 18–75 yearsPersistent unilateral cochlear tinnitus
AM-101 by Auris Medical and AltamiraAltamira Therapeutics Compare	Small Molecule	Stage: Phase 3Status: Discontinued	Adults · 18–75 yearsAcute post-injury tinnitus
NHPN-1010Otologic Pharmaceutics Compare	Small Molecule	Stage: Phase 1Status: Completed	Adults · 18–55 yearsHazardous noise or blast exposure
Isosorbide Oral Solution by Lunan Better PharmaceuticalLunan Better Pharmaceutical Co., Ltd. Compare	Small Molecule	Stage: Phase 2/3Status: Active	Adults · 18–65 yearsRecurrent unilateral Ménière’s disease
Neramexane by MerzMerz Pharmaceuticals GmbH Compare	Small Molecule	Stage: Phase 3Status: Completed	Adults · 18–75 yearsPersistent subjective tinnitus

AC102 by AudioCure Pharma

AudioCure Pharma · Small Molecule · Phase 2

ActiveTherapeuticStronger sources

Population

Adults · 18–85 years

Recent severe unilateral ISSNHL

Evidence

trial

Confidence

91%

Indications

Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing LossTinnitus

SPI-1005 by Sound Pharmaceuticals

Sound Pharmaceuticals · Small Molecule · Phase 3

ActiveTherapeuticStronger sources

Population

Adults · 18–75 years

Active Ménière’s disease

Evidence

trial

Confidence

90%

Indications

Hearing LossSensorineural Hearing LossNoise-Induced Hearing LossTinnitus

OTO-313 by Otonomy

Otonomy · Small Molecule · Phase 2

DiscontinuedTherapeutic

Population

Adults · 18–75 years

Persistent unilateral cochlear tinnitus

Evidence

company

Confidence

96%

Indications

Tinnitus

AM-101 by Auris Medical and Altamira

Altamira Therapeutics · Small Molecule · Phase 3

DiscontinuedTherapeutic

Population

Adults · 18–75 years

Acute post-injury tinnitus

Evidence

trial

Confidence

93%

Indications

Tinnitus

Otologic Pharmaceutics · Small Molecule · Phase 1

CompletedTherapeutic

Population

Adults · 18–55 years

Hazardous noise or blast exposure

Evidence

company

Confidence

89%

Indications

Hearing LossSensorineural Hearing LossNoise-Induced Hearing LossTinnitus

Isosorbide Oral Solution by Lunan Better Pharmaceutical

Lunan Better Pharmaceutical Co., Ltd. · Small Molecule · Phase 2/3

ActiveTherapeutic

Population

Adults · 18–65 years

Recurrent unilateral Ménière’s disease

Evidence

trial

Confidence

88%

Indications

Hearing LossTinnitus

Neramexane by Merz

Merz Pharmaceuticals GmbH · Small Molecule · Phase 3

CompletedTherapeutic

Population

Adults · 18–75 years

Persistent subjective tinnitus

Evidence

publication

Confidence

86%

Indications

Tinnitus

A listing is not proof of safety or effectiveness. Approval and availability may vary by indication and country.

How records are checked